Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models
International Journal of Cancer - United States
doi 10.1002/ijc.32224
Full Text
Open PDFAbstract
Available in full text
Date
March 13, 2019
Authors
Publisher
Wiley